Optimizing Pazopanib Exposure in RCC Patients through Therapeutic Drug Monitoring Followed by Intrapatient Dose Escalation

Trial Profile

Optimizing Pazopanib Exposure in RCC Patients through Therapeutic Drug Monitoring Followed by Intrapatient Dose Escalation

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms OPERA
  • Most Recent Events

    • 30 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
    • 14 Apr 2016 Status changed from recruiting to discontinued.
    • 14 May 2014 New source identified and integrated (ClinicalTrials.gov record: NCT02089802)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top